0001298709-23-000015.txt : 20230418
0001298709-23-000015.hdr.sgml : 20230418
20230418160651
ACCESSION NUMBER: 0001298709-23-000015
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230417
FILED AS OF DATE: 20230418
DATE AS OF CHANGE: 20230418
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Krishnan Krish S
CENTRAL INDEX KEY: 0001298709
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38210
FILM NUMBER: 23826889
MAIL ADDRESS:
STREET 1: 2100 WHARTON STREET
STREET 2: SUITE 701
CITY: PITTSBURGH
STATE: PA
ZIP: 15203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Krystal Biotech, Inc.
CENTRAL INDEX KEY: 0001711279
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 821080209
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2100 WHARTON STREET
STREET 2: SUITE 701
CITY: PITTSBURGH
STATE: PA
ZIP: 15203
BUSINESS PHONE: (412) 586-5830
MAIL ADDRESS:
STREET 1: 2100 WHARTON STREET
STREET 2: SUITE 701
CITY: PITTSBURGH
STATE: PA
ZIP: 15203
4
1
wf-form4_168184839404028.xml
FORM 4
X0407
4
2023-04-17
0
0001711279
Krystal Biotech, Inc.
KRYS
0001298709
Krishnan Krish S
C/O KRYSTAL BIOTECH, INC.
2100 WHARTON STREET, SUITE 701
PITTSBURGH
PA
15203
1
1
1
0
President and CEO
1
Common Stock
2023-04-17
4
S
0
1050
85.5483
D
1733288
D
Common Stock
2023-04-17
4
S
0
4298
86.7964
D
1728990
D
Common Stock
2023-04-17
4
S
0
9428
87.4113
D
1719562
D
Common Stock
2023-04-17
4
S
0
9724
88.4062
D
1709838
D
Common Stock
2023-04-17
4
S
0
500
89.1175
D
1709338
D
Common Stock
2023-04-17
4
S
0
1050
85.5487
D
1676213
I
By Spouse
Common Stock
2023-04-17
4
S
0
4297
86.7964
D
1671916
I
By Spouse
Common Stock
2023-04-17
4
S
0
9429
87.4114
D
1662487
I
By Spouse
Common Stock
2023-04-17
4
S
0
9724
88.4062
D
1652763
I
By Spouse
Common Stock
2023-04-17
4
S
0
500
89.1175
D
1652263
I
By Spouse
Common Stock
90000
I
By Krishnan Spousal Trust
Common Stock
50000
I
By Krishnan Family Trust
The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and contemplated quarterly sales of 25,000 shares with a limit price of $80.00 per share. The Rule 10b5-1 trading plan has now reached the maximum number of shares to be sold under such plan.
The transaction was executed in multiple trades ranging from $85.0500 to $86.0000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $86.0500 to $87.0450. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $87.0500 to $88.0300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $88.0500 to $89.0100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $89.0650 to $89.2300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Suma Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and contemplated quarterly sales of 25,000 shares with a limit price of $80.00 per share. The Rule 10b5-1 trading plan has now reached the maximum number of shares to be sold under such plan.
These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Suma Krishnan.
Directly beneficially owned by Suma M. Krishnan, the spouse of the Reporting Person.
Directly beneficially owned by the Krishnan Family Trust. The Reporting Person and his spouse are each joint beneficial owners of the trust with joint voting and investment control.
/s/ Krish S. Krishnan
2023-04-18